Tags

Type your tag names separated by a space and hit enter

Narrowband ultraviolet B phototherapy in children with moderate-to-severe eczema: a comparative cohort study.

Abstract

BACKGROUND

There is only retrospective evidence for the efficacy of narrowband ultraviolet B (NB-UVB) in children with eczema.

OBJECTIVES

To measure the difference in means for objective scores [Six Area Six Sign Atopic Dermatitis score (SASSAD), percentage surface area] and quality-of-life scores, between patients treated with NB-UVB and unexposed cohorts at the end of treatment, and 3 and 6 months post-treatment.

METHODS

Twenty-nine children aged 3-16 years for whom NB-UVB was indicated, were scored prospectively using SASSAD and percentage surface area involvement at baseline, at 12 weeks (end of treatment) and 3 and 6 months post-NB-UVB. Their scores were compared with those of unexposed children (n = 26) for whom NB-UVB phototherapy was indicated and offered, but who chose not to undertake treatment.

RESULTS

There was a 61% reduction in mean SASSAD score in the NB-UVB cohort compared with an increase of 6% in the unexposed cohort. Mean SASSAD score for the NB-UVB cohort at the end of treatment was 11.6 vs. 24.8 for the unexposed; difference in means -13.2 [95% confidence interval (CI) -18.7 to -7.7, P < 0.0001]. Mean surface area involvement at the end of treatment was 11% for the NB-UVB cohort vs. 36% for the unexposed cohort; difference in means -25% (95% CI -34% to -16%, P < 0.0001). Subjective and quality-of-life scores showed significant difference between cohorts at the end of treatment (P < 0.05). Objective scores remained significantly lower than in the unexposed cohort 3 and 6 months after treatment.

CONCLUSION

NB-UVB is clinically effective and improves quality of life in children with moderate-to-severe eczema. The effect is maintained for 6 months after treatment.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Dermatology, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, NE1 4LP, U.K.

    ,

    Source

    The British journal of dermatology 170:1 2014 Jan pg 150-6

    MeSH

    Adolescent
    Child
    Child, Preschool
    Eczema
    Female
    Humans
    Male
    Prospective Studies
    Remission Induction
    Treatment Outcome
    Ultraviolet Therapy

    Pub Type(s)

    Comparative Study
    Evaluation Studies
    Journal Article
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    23937117

    Citation

    Darné, S, et al. "Narrowband Ultraviolet B Phototherapy in Children With Moderate-to-severe Eczema: a Comparative Cohort Study." The British Journal of Dermatology, vol. 170, no. 1, 2014, pp. 150-6.
    Darné S, Leech SN, Taylor AE. Narrowband ultraviolet B phototherapy in children with moderate-to-severe eczema: a comparative cohort study. Br J Dermatol. 2014;170(1):150-6.
    Darné, S., Leech, S. N., & Taylor, A. E. (2014). Narrowband ultraviolet B phototherapy in children with moderate-to-severe eczema: a comparative cohort study. The British Journal of Dermatology, 170(1), pp. 150-6. doi:10.1111/bjd.12580.
    Darné S, Leech SN, Taylor AE. Narrowband Ultraviolet B Phototherapy in Children With Moderate-to-severe Eczema: a Comparative Cohort Study. Br J Dermatol. 2014;170(1):150-6. PubMed PMID: 23937117.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Narrowband ultraviolet B phototherapy in children with moderate-to-severe eczema: a comparative cohort study. AU - Darné,S, AU - Leech,S N, AU - Taylor,A E M, PY - 2013/08/03/accepted PY - 2013/8/14/entrez PY - 2013/8/14/pubmed PY - 2015/1/15/medline SP - 150 EP - 6 JF - The British journal of dermatology JO - Br. J. Dermatol. VL - 170 IS - 1 N2 - BACKGROUND: There is only retrospective evidence for the efficacy of narrowband ultraviolet B (NB-UVB) in children with eczema. OBJECTIVES: To measure the difference in means for objective scores [Six Area Six Sign Atopic Dermatitis score (SASSAD), percentage surface area] and quality-of-life scores, between patients treated with NB-UVB and unexposed cohorts at the end of treatment, and 3 and 6 months post-treatment. METHODS: Twenty-nine children aged 3-16 years for whom NB-UVB was indicated, were scored prospectively using SASSAD and percentage surface area involvement at baseline, at 12 weeks (end of treatment) and 3 and 6 months post-NB-UVB. Their scores were compared with those of unexposed children (n = 26) for whom NB-UVB phototherapy was indicated and offered, but who chose not to undertake treatment. RESULTS: There was a 61% reduction in mean SASSAD score in the NB-UVB cohort compared with an increase of 6% in the unexposed cohort. Mean SASSAD score for the NB-UVB cohort at the end of treatment was 11.6 vs. 24.8 for the unexposed; difference in means -13.2 [95% confidence interval (CI) -18.7 to -7.7, P < 0.0001]. Mean surface area involvement at the end of treatment was 11% for the NB-UVB cohort vs. 36% for the unexposed cohort; difference in means -25% (95% CI -34% to -16%, P < 0.0001). Subjective and quality-of-life scores showed significant difference between cohorts at the end of treatment (P < 0.05). Objective scores remained significantly lower than in the unexposed cohort 3 and 6 months after treatment. CONCLUSION: NB-UVB is clinically effective and improves quality of life in children with moderate-to-severe eczema. The effect is maintained for 6 months after treatment. SN - 1365-2133 UR - https://www.unboundmedicine.com/medline/citation/23937117/full_citation L2 - https://doi.org/10.1111/bjd.12580 DB - PRIME DP - Unbound Medicine ER -